Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 482 articles:
HTML format



Single Articles


    December 2021
  1. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    PubMed     Abstract available



  2. 2021 Hepatology Referees (Volumes 73 and 74).
    Hepatology. 2021;74:3565-3569.
    PubMed    


  3. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2931-2934.
    PubMed    


    November 2021
  4. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    PubMed     Abstract available


  5. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
    Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
    Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
    PubMed     Abstract available


  6. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
    Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
    Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
    PubMed     Abstract available


  7. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
    PubMed     Abstract available


  8. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    PubMed     Abstract available


  9. TIAN L, Zhao L, Sze KM, Kam CS, et al
    Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
    PubMed     Abstract available


  10. YANG J, Ye J, Ma T, Tang F, et al
    TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
    PubMed     Abstract available


  11. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    PubMed     Abstract available


  12. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    PubMed     Abstract available


  13. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2329-2332.
    PubMed    


    October 2021
  14. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    PubMed     Abstract available


  15. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available


  16. MANCUSO A
    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    PubMed     Abstract available


  17. LUCE E, Steichen C, Allouche M, Messina A, et al
    In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
    Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
    PubMed     Abstract available


  18. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    PubMed     Abstract available


  19. ZHOU J, Guo L, Ma T, Qiu T, et al
    N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
    PubMed     Abstract available



  20. Correction of HEPATOLOGY 2020;71:259-274.
    Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
    PubMed    


  21. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    PubMed     Abstract available


  22. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    PubMed     Abstract available


  23. LIU N, Steer CJ, Song G
    MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
    PubMed     Abstract available


  24. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available


  25. ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1727-1729.
    PubMed    


  26. MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
    Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
    Hepatology. 2021;74:1825-1844.
    PubMed     Abstract available


    September 2021
  27. FANG Y, Zhan Y, Xie Y, Du S, et al
    Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
    PubMed     Abstract available


  28. LI H, Liu G, Wan X, Zhou L, et al
    ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
    PubMed     Abstract available


  29. GARCIA-TSAO G
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    PubMed     Abstract available


  30. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    PubMed     Abstract available


  31. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    PubMed     Abstract available


  32. ZHAO Y, Gao L, Jiang C, Chen J, et al
    The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
    PubMed     Abstract available


  33. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    PubMed     Abstract available


  34. ZHAI LL, Zhen SH, Tang ZG
    Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
    PubMed     Abstract available


  35. FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
    Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
    PubMed     Abstract available


  36. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    PubMed     Abstract available


  37. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    PubMed     Abstract available


  38. DUAN J, Wang Z, Duan R, Yang C, et al
    Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
    PubMed     Abstract available


  39. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    PubMed     Abstract available


  40. SHAH BJ, Onken JE, Edgar L, Jou JH, et al
    Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
    PubMed    


  41. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    PubMed     Abstract available


  42. ZHANG X, Yang H, Zeng S, Tian S, et al
    Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
    Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
    PubMed     Abstract available


  43. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    PubMed     Abstract available


  44. GORES GJ, Malhi H
    Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
    PubMed     Abstract available


  45. KHAN IW, Ali MA, Lau DTY, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1137-1140.
    PubMed    


  46. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    PubMed     Abstract available


    August 2021
  47. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    PubMed     Abstract available


  48. PLUMMER MD, Regenstein F
    Light chain deposition disease: an unusual cause of portal hypertension.
    Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
    PubMed     Abstract available


  49. FU J, Hu F, Ma T, Zhao WJ, et al
    A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
    PubMed     Abstract available


  50. IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
    Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
    Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
    PubMed     Abstract available


  51. FAN S, Gao Y, Qu A, Jiang Y, et al
    YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
    PubMed     Abstract available


  52. FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
    Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
    PubMed     Abstract available


  53. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    PubMed     Abstract available


  54. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    PubMed     Abstract available


  55. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    PubMed     Abstract available


  56. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    PubMed     Abstract available


  57. WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2021;74:539-542.
    PubMed    


  58. FIX OK, Blumberg EA, Chang KM, Chu J, et al
    American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
    Hepatology. 2021;74:1049-1064.
    PubMed     Abstract available


  59. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    PubMed     Abstract available


    July 2021
  60. WIN S, Min RWM, Zhang J, Kanel G, et al
    Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
    PubMed     Abstract available


  61. ZHANG Z, Ji Z, He J, Lu Y, et al
    GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
    PubMed     Abstract available


  62. SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
    Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
    PubMed     Abstract available


  63. MA L, Xu A, Kang L, Cong R, et al
    LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
    PubMed     Abstract available


  64. LIU G, Wang N, Zhang C, Li M, et al
    ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
    PubMed     Abstract available


  65. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available


  66. HU M, Zhang D, Xu H, Zhang Y, et al
    Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
    PubMed     Abstract available


  67. HE Q, Liu M, Huang W, Chen X, et al
    IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
    Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
    PubMed     Abstract available


  68. YANG Q, Chen X, Zhang Y, Hu S, et al
    The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
    Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
    PubMed     Abstract available


  69. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available


  70. MILLER BM, Oderberg IM, Goessling W
    The Hepatic Nervous System in Development, Regeneration, and Disease.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
    PubMed     Abstract available


  71. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
    Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
    PubMed     Abstract available


  72. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available


  73. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available


  74. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available


  75. BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1-4.
    PubMed    


    June 2021
  76. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available


  77. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
    SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
    PubMed     Abstract available


  78. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    PubMed     Abstract available


  79. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
    Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
    PubMed     Abstract available


  80. CHOLANKERIL G, Kanwal F
    Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
    PubMed     Abstract available


  81. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
    Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
    Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
    PubMed     Abstract available


  82. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available


  83. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available


  84. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available


  85. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available


  86. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available


  87. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available


  88. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
    Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
    PubMed     Abstract available


  89. SHAH V, Iwakiri Y, Boyer JL
    Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
    PubMed     Abstract available


  90. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    PubMed     Abstract available


  91. CHO K, Ro SW, Lee HW, Moon H, et al
    YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
    Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
    PubMed     Abstract available


  92. CHEN B, Wu JX, Cheng SH, Wang LM, et al
    Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
    PubMed     Abstract available


  93. JINDAL A, Jagdish RK
    Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
    PubMed     Abstract available


  94. WONG TC, Lee VH, Law AL, Pang HH, et al
    Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
    PubMed     Abstract available


  95. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    PubMed     Abstract available


  96. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
    Hepatology Highlights.
    Hepatology. 2021;73:2085-2088.
    PubMed    


  97. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    PubMed     Abstract available


    May 2021
  98. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
    MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
    PubMed     Abstract available


  99. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available


  100. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
    Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
    PubMed     Abstract available


  101. YI C, Chen L, Ling Z, Liu L, et al
    Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
    PubMed     Abstract available


  102. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  103. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  104. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available


  105. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available


  106. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available


  107. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available


  108. PEISELER M, Tacke F
    An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
    Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
    PubMed     Abstract available


  109. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available


  110. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available


  111. DICHTEL LE
    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    PubMed     Abstract available


  112. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
    Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
    PubMed     Abstract available


  113. LIU Y, Dou X, Zhou WY, Ding M, et al
    Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
    PubMed     Abstract available


  114. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1627-1630.
    PubMed    



  115. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


    April 2021
  116. SHENG J, Kohno S, Okada N, Okahashi N, et al
    Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
    PubMed     Abstract available


  117. BUCKARMA E, Smoot R
    Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
    PubMed     Abstract available


  118. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available


  119. LUO Y, Gao Y, Liu W, Yang Y, et al
    MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
    PubMed     Abstract available


  120. YANG X, Sun D, Xiang H, Wang S, et al
    Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
    PubMed     Abstract available


  121. LIU D, Pang J, Shao W, Gu J, et al
    Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
    Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
    PubMed     Abstract available


  122. XU X, Ye L, Zhang Q, Shen H, et al
    Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
    PubMed     Abstract available


  123. SUN D, Yang X, Wu B, Zhang XJ, et al
    Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
    PubMed     Abstract available


  124. WING-SUM CHEU J, Chak-Lui Wong C
    Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
    Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
    PubMed     Abstract available


  125. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
    Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
    Hepatology. 2021;73:1521-1530.
    PubMed     Abstract available


  126. FU Y, Zhu R, Bai T, Han P, et al
    Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Hepatology. 2021;73:1509-1520.
    PubMed     Abstract available


  127. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1245-1247.
    PubMed    



  128. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  129. DE ZEGHER F, Ibanez L
    Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
    Hepatology. 2021;73:1623-1624.
    PubMed    


  130. GOLRIZ M, Ramouz A, Mehrabi A
    Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
    Hepatology. 2021;73:1621.
    PubMed    


  131. DHAR D, Loomba R
    Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
    Hepatology. 2021;73:1248-1250.
    PubMed    


  132. XU H, Tian Y, Tang D, Zou S, et al
    An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
    Hepatology. 2021;73:1327-1345.
    PubMed     Abstract available


  133. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    PubMed     Abstract available


  134. ALKHOURI N, Reddy GK, Lawitz E
    Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
    Hepatology. 2021;73:1581-1593.
    PubMed    


  135. ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
    Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
    Hepatology. 2021;73:1611-1614.
    PubMed    


  136. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    PubMed     Abstract available


  137. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    PubMed     Abstract available


    March 2021
  138. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed     Abstract available


  139. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available


  140. DOURTHE C, Julien C, Di Tommaso S, Dupuy JW, et al
    Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches.
    Hepatology. 2021 Mar 23. doi: 10.1002/hep.31826.
    PubMed     Abstract available


  141. BLOOM PP, Matherly S, Kumar S, Koh C, et al
    Professional Use of Social Media by Hepatology Providers.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31824.
    PubMed     Abstract available


  142. SALEM R, Johnson GE, Kim E, Riaz A, et al
    Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
    PubMed     Abstract available


  143. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available


  144. ZHAO Y, Wang J, Liu WN, Fong SY, et al
    Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31812.
    PubMed     Abstract available


  145. LEE YT, Wang JJ, Luu M, Tseng HR, et al
    State-Level Hepatocellular Carcinoma Incidence and Association with Obesity and Physical Activity in the United States.
    Hepatology. 2021 Mar 17. doi: 10.1002/hep.31811.
    PubMed     Abstract available


  146. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available


  147. SANO A, Kakazu E, Hamada S, Inoue J, et al
    Steatotic hepatocytes release mature VLDL via methionine and tyrosine metabolism in a Keap1-Nrf2 dependent manner.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31808.
    PubMed     Abstract available


  148. ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
    Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
    PubMed     Abstract available


  149. MEUNIER L, Hirsch TZ, Caruso S, Imbeaud S, et al
    DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31796.
    PubMed     Abstract available


  150. WU H, Xu X, Zheng A, Wang W, et al
    TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
    PubMed     Abstract available


  151. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available


  152. SATHIYAPALAN A, Legault K, van der Pol CB, Meyers BM, et al
    Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated with Lenvatinib.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31794.
    PubMed     Abstract available


  153. SONG M, He J, Pan QZ, Yang J, et al
    Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression.
    Hepatology. 2021 Mar 8. doi: 10.1002/hep.31792.
    PubMed     Abstract available


  154. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available



  155. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  156. HANIF H, Ali MJ, Chen HW, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;73:877-880.
    PubMed    


  157. BLOOM PP, Meyerowitz EA, Reinus Z, Daidone M, et al
    Liver Biochemistries in Hospitalized Patients With COVID-19.
    Hepatology. 2021;73:890-900.
    PubMed     Abstract available


  158. MCHENRY SA, Davidson NO
    Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
    Hepatology. 2021;73:884-886.
    PubMed    


  159. MELLINGER J, Winder GS, Fernandez AC
    Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
    Hepatology. 2021;73:1207-1212.
    PubMed    


  160. WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
    Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
    Hepatology. 2021;73:1199-1206.
    PubMed    


  161. PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
    Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
    Hepatology. 2021;73:1233-1235.
    PubMed    


  162. GODBEE M, Jakate S, Eswaran S
    A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
    Hepatology. 2021;73:1230-1232.
    PubMed    


  163. YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
    From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
    Hepatology. 2021;73:1194-1198.
    PubMed     Abstract available


  164. PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
    Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
    Hepatology. 2021;73:1176-1193.
    PubMed     Abstract available


    February 2021
  165. NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
    Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
    PubMed     Abstract available


  166. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available


  167. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available


  168. SU T, Huang M, Liao J, Lin S, et al
    Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m(6) A mRNA Methylation Dependent Mechanism.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31766.
    PubMed     Abstract available


  169. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  170. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available


  171. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available


  172. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available


  173. BARROW F, Khan S, Fredrickson G, Wang H, et al
    Microbiota-Driven Activation of Intrahepatic B Cells Aggravates Nonalcoholic Steatohepatitis through Innate and Adaptive Signaling.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31755.
    PubMed     Abstract available


  174. QU C, He L, Yao N, Li J, et al
    Myofibroblast-specific Msi2 knockout inhibits hepatocellular carcinoma progression in a mouse model.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31754.
    PubMed     Abstract available


  175. LAN T, Yu Y, Zhang J, Li H, et al
    Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
    PubMed     Abstract available


  176. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available


  177. YOU Z, Li Y, Wang Q, Zhao Z, et al
    The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident Memory T Cells in Autoimmune Hepatitis.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31739.
    PubMed     Abstract available


  178. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available


  179. ROSENTHAL SB, Liu X, Ganguly S, Dhar D, et al
    Heterogeneity of hepatic stellate cells in a mouse model of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31743.
    PubMed     Abstract available


  180. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available


  181. KE W, Cai De L, Jian Nan S, Chun Nian W, et al
    Primary Hepatic Squamous Cell Carcinoma With MSI-H Shows Good Response to PD-1 Inhibitor as Adjuvant Therapy.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31737.
    PubMed     Abstract available


  182. TAO J, Krutsenko Y, Moghe A, Singh S, et al
    Nrf2 and beta-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications.
    Hepatology. 2021 Feb 2. doi: 10.1002/hep.31730.
    PubMed     Abstract available


  183. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available



  184. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:1.
    PubMed    


  185. BUCKHOLZ A, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;73:475-478.
    PubMed    


  186. KARDASHIAN A, Wilder J, Terrault NA, Price JC, et al
    Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.
    Hepatology. 2021;73:811-820.
    PubMed     Abstract available


  187. DI GUGLIELMO MD, Perito ER
    To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
    Hepatology. 2021;73:483-485.
    PubMed    


  188. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.
    PubMed    


  189. GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
    Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
    Hepatology. 2021;73:560-570.
    PubMed     Abstract available


  190. TILG H, Adolph TE, Moschen AR
    Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
    Hepatology. 2021;73:833-842.
    PubMed    


  191. AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
    Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
    Hepatology. 2021;73:726-737.
    PubMed     Abstract available


  192. JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
    TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
    Hepatology. 2021;73:776-794.
    PubMed     Abstract available


  193. HU W, Zheng S, Guo H, Dai B, et al
    PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
    Hepatology. 2021;73:674-691.
    PubMed     Abstract available


  194. ZUO Q, He J, Zhang S, Wang H, et al
    PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
    Hepatology. 2021;73:644-660.
    PubMed     Abstract available


    January 2021
  195. KALASEKAR SM, Garrido-Laguna I, Evason KJ
    Immune Checkpoint Inhibitors in Novel Combinations for Hepatocellular Carcinoma.
    Hepatology. 2021 Jan 12. doi: 10.1002/hep.31706.
    PubMed     Abstract available


  196. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available


  197. LUCE E, Messina A, Duclos-Vallee JC, Dubart-Kupperschmitt A, et al
    Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes.
    Hepatology. 2021 Jan 8. doi: 10.1002/hep.31705.
    PubMed     Abstract available


  198. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available


  199. SATIYA J, Kaur SP, Lau DTY, Hejazifar N, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1-3.
    PubMed    


  200. JAESCHKE H, Ramachandran A
    Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
    Hepatology. 2021;73:467-468.
    PubMed    


  201. TANG X, Wang XJ
    REPLY.
    Hepatology. 2021;73:468-469.
    PubMed    


  202. CHOI J, Lim YS
    REPLY.
    Hepatology. 2021;73:467.
    PubMed    


  203. CASEY L, Aday A, Rule J, Lee WM, et al
    Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
    Hepatology. 2021;73:465.
    PubMed    


  204. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    PubMed    


  205. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
    Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:318-365.
    PubMed    


  206. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
    Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
    Hepatology. 2021;73:452-455.
    PubMed    


  207. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
    Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
    Hepatology. 2021;73:233-246.
    PubMed     Abstract available


  208. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
    Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
    Hepatology. 2021;73:268-281.
    PubMed     Abstract available


  209. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
    E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
    Hepatology. 2021;73:303-317.
    PubMed     Abstract available


  210. GU L, Zhu Y, Lin X, Lu B, et al
    The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
    Hepatology. 2021;73:160-174.
    PubMed     Abstract available


  211. ZHOU B, Liu C, Xu L, Yuan Y, et al
    N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
    Hepatology. 2021;73:91-103.
    PubMed     Abstract available


  212. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
    Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Hepatology. 2021;73:186-203.
    PubMed     Abstract available


    December 2020
  213. PINATO DJ, Fessas P, Sapisochin G, Marron TU, et al
    Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.
    Hepatology. 2020 Dec 28. doi: 10.1002/hep.31697.
    PubMed     Abstract available


  214. ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
    Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
    Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
    PubMed     Abstract available


  215. ANANIA FA, Dimick-Santos L, Mehta R, Toerner J, et al
    Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Hepatology. 2020 Dec 19. doi: 10.1002/hep.31687.
    PubMed     Abstract available


  216. VIVEIROS A, Beliveau V, Panzer M, Schaefer B, et al
    Neurodegeneration in Hepatic and Neurologic Wilson Disease.
    Hepatology. 2020 Dec 14. doi: 10.1002/hep.31681.
    PubMed     Abstract available


  217. LIOU H, Mody K, Boyle AW, Keaveny AP, et al
    Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive Hepatocellular Carcinoma Resulting in Complete Pathologic Response.
    Hepatology. 2020 Dec 7. doi: 10.1002/hep.31675.
    PubMed     Abstract available


  218. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available


  219. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available


  220. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available


  221. BUCKHOLZ A, Brown RS Jr, Trivedi H, Khan MM, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1893-1896.
    PubMed    


  222. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
    Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
    Hepatology. 2020;72:2228-2230.
    PubMed    


  223. MEHTA N, Yao FY
    Reply.
    Hepatology. 2020;72:2243-2244.
    PubMed    


  224. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    PubMed    


  225. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    PubMed    


    November 2020
  226. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available


  227. HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
    DNA methylation profiling of human hepatocarcinogenesis.
    Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
    PubMed     Abstract available


  228. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    PubMed     Abstract available


  229. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available


  230. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available


  231. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available


  232. LI S, Liu Y, Bai Y, Chen M, et al
    RHOF promotes hepatocellular carcinoma metastasis by altering the metabolic status of cancer cells via RAB3D.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31641.
    PubMed     Abstract available


  233. RICH NE, Marrero JA, Singal AG
    Reply: Wang et al, "Should growth pattern of hepatocellular carcinoma be constant and homogenous?"
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31638.
    PubMed     Abstract available


  234. WANG H, Mao Y, Huang M
    Letter to the Editors: should growth pattern of hepatocellular carcinoma be constant and homogenous?
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31640.
    PubMed     Abstract available


  235. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available


  236. GU X, Sun R, Chen L, Chu S, et al
    Neutral ceramidase mediates nonalcoholic steatohepatitis by regulating monounsaturated fatty acids and gut IgA(+) B cells.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31628.
    PubMed     Abstract available


  237. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available


  238. LOOMBA R
    MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.
    PubMed     Abstract available


  239. HUO TI, Liu PH, Hsu CY
    Using circulating biomarkers to stage hepatocellular carcinoma: Pitfalls and limitations.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31618.
    PubMed     Abstract available


  240. SUN L, Guan A, Liu M, Mao Y, et al
    Letter to the editor: Comment on "HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk".
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31621.
    PubMed     Abstract available


  241. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available


  242. GAO J, Wei B, Liu M, Hirsova P, et al
    Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
    Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
    PubMed     Abstract available


  243. KURODA H, Abe T, Fujiwara Y, Nagasawa T, et al
    Contrast-enhanced ultrasonography-based hepatic perfusion for early prediction of prognosis in acute liver failure.
    Hepatology. 2020 Nov 5. doi: 10.1002/hep.31615.
    PubMed     Abstract available


  244. KRISHNAN MS, Rajan Kd A, Park J, Arjunan V, et al
    Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31614.
    PubMed     Abstract available


  245. RUSSO NW, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1505-1508.
    PubMed    


  246. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    PubMed     Abstract available


  247. ALKHOURI N, Kohli A, Loomba R, Harrison SA, et al
    Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic.
    Hepatology. 2020;72:1509-1513.
    PubMed    


  248. BERTOLINI A, van de Peppel IP, Bodewes FAJA, Moshage H, et al
    Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.
    Hepatology. 2020;72:1864-1872.
    PubMed    


  249. CAVE MC
    Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
    Hepatology. 2020;72:1518-1521.
    PubMed    


  250. JAESCHKE H, Ramachandran A
    Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
    Hepatology. 2020;72:1873-1876.
    PubMed    


  251. SINGH S, Verma N, Singh V
    Letter to the Editor: MELD-Lactate-the New Kid on the Block.
    Hepatology. 2020;72:1883.
    PubMed    


    October 2020
  252. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    PubMed     Abstract available


  253. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available


  254. STARLINGER P, Pereyra D, Hackl H, Ortmayr G, et al
    Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment during Hepatic Surgery.
    Hepatology. 2020 Oct 20. doi: 10.1002/hep.31601.
    PubMed     Abstract available


  255. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available


  256. TAN HY, Wang N, Zhang C, Chan YT, et al
    LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
    Hepatology. 2020 Oct 17. doi: 10.1002/hep.31600.
    PubMed     Abstract available


  257. LI XJ, Li QL, Ju LG, Zhao C, et al
    Deficiency of histone methyltransferase SETD2 in liver leads to abnormal lipid metabolism and hepatocarcinoma.
    Hepatology. 2020 Oct 15. doi: 10.1002/hep.31594.
    PubMed     Abstract available


  258. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available


  259. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available


  260. YUAN G, Yao J, Yu J, Xie X, et al
    Letter to the Editors: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31590.
    PubMed     Abstract available


  261. WONG TC, Yan-Yue Fung J, Pang HH, Leung CK, et al
    Analysis of survival benefits of living vs. deceased donor liver transplant in high MELD and hepatorenal syndrome.
    Hepatology. 2020 Oct 2. doi: 10.1002/hep.31584.
    PubMed     Abstract available


  262. ANTKOWIAK M, Green RM
    Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
    Hepatology. 2020;72:1166-1168.
    PubMed    


  263. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    PubMed    


  264. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  265. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available


  266. CHANDLER RJ, Venturoni LE, Liao J, Hubbard BT, et al
    Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31570.
    PubMed     Abstract available


  267. OOSHIO T, Yamamoto M, Fujii K, Xin B, et al
    Hepatocyte MKK7 Contributes to Restoration of the Liver Parenchyma Following Injury.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31565.
    PubMed     Abstract available


  268. ZHANG BH, Cai YS, Song JL, Lyu T, et al
    Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in CHB Patients.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31563.
    PubMed     Abstract available


  269. GOH MJ, Sinn DH, Woo SY, Kim S, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2020 Sep 22. doi: 10.1002/hep.31567.
    PubMed     Abstract available


  270. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    PubMed     Abstract available


  271. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    PubMed     Abstract available


  272. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    PubMed     Abstract available


  273. MORRIS JS, Hassan MM, Zohner YE, Wang Z, et al
    HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31555.
    PubMed     Abstract available


  274. YAZDANI HO, Kaltenmeier C, Morder K, Moon J, et al
    Exercise training decreases hepatic injury via changes in immune response to liver ischemia/reperfusion in mice.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31552.
    PubMed     Abstract available


  275. VERMA M, Younossi Z
    Integrating Patient Reported Outcomes within Routine Hepatology Care: A Prompt to Action.
    Hepatology. 2020 Sep 12. doi: 10.1002/hep.31550.
    PubMed     Abstract available


  276. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    PubMed     Abstract available


  277. ZHEN S, Cai X
    Letter to Editor: Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31543.
    PubMed     Abstract available


  278. PIANO S, Gambino C, Vettore E, Calvino V, et al
    Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Hepatology. 2020 Sep 1. doi: 10.1002/hep.31529.
    PubMed     Abstract available


  279. PHIPPS MM, Barraza LH, LaSota ED, Sobieszczyk ME, et al
    Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.
    Hepatology. 2020;72:807-817.
    PubMed     Abstract available


  280. DA BL, Im GY, Schiano TD
    Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.
    Hepatology. 2020;72:1102-1108.
    PubMed     Abstract available


  281. KAPLAN A, Rosenblatt R, Buckholz A, Kumar S, et al
    Hepatology Highlights.
    Hepatology. 2020;72:791-793.
    PubMed    


  282. JIANG X, Ding WX
    Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
    Hepatology. 2020;72:797-800.
    PubMed    


  283. GUICCIARDI ME, Nakao Y, Gores GJ
    The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
    Hepatology. 2020;72:1139-1141.
    PubMed    


  284. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    PubMed    


  285. WEISS TS, Melter M, Dayoub R
    Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
    Hepatology. 2020;72:1156-1157.
    PubMed    


  286. VERMA AK, Gandhi CR
    Reply.
    Hepatology. 2020;72:1157-1158.
    PubMed    


    August 2020
  287. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    PubMed     Abstract available


  288. LOOMBA R, Ling L, Dinh DM, DePaoli AM, et al
    The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523.
    PubMed     Abstract available


  289. BHUSHAN B, Molina L, Koral K, Stoops JW, et al
    Yap is crucial for CAR-driven hepatocyte proliferation, but not for induction of drug metabolism genes in mice.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31521.
    PubMed     Abstract available


  290. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available


  291. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    PubMed     Abstract available


  292. BANINI BA, Alwatari Y, Ogden N, Gershman E, et al
    Letter to Editor: Response to Commentary "Midodrine for Hepatic Hydrothorax".
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31512.
    PubMed     Abstract available


  293. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31502.
    PubMed     Abstract available


  294. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available


  295. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available


  296. VERNA EC, Serper M, Chu J, Corey K, et al
    Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation.
    Hepatology. 2020 Aug 2. doi: 10.1002/hep.31491.
    PubMed     Abstract available


  297. WANGENSTEEN KJ, Chang KM
    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    PubMed     Abstract available


  298. TALAT A, Shah PA, Lau DTY, Russo NW, et al
    Hepatology Highlights.
    Hepatology. 2020;72:369-370.
    PubMed    


  299. SERPER M, Cubell AW, Deleener ME, Casher TK, et al
    Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?
    Hepatology. 2020;72:723-728.
    PubMed     Abstract available


  300. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    PubMed    


  301. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
    Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
    Hepatology. 2020;72:770-771.
    PubMed    


  302. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
    Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;72:785.
    PubMed    


  303. WEI L, Chang PEJ, Anstee QM
    Reply.
    Hepatology. 2020;72:786.
    PubMed    


  304. KWON HM, Hwang GS
    Reply.
    Hepatology. 2020;72:784.
    PubMed    


  305. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
    Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Hepatology. 2020;72:781.
    PubMed    


    July 2020
  306. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    PubMed     Abstract available


  307. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    PubMed     Abstract available


  308. SABERI B, Naik H, Overbey JR, Erwin AL, et al
    Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium.
    Hepatology. 2020 Jul 18. doi: 10.1002/hep.31460.
    PubMed     Abstract available


  309. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    PubMed     Abstract available


  310. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    PubMed     Abstract available


  311. WEI X, Zhao L, Ren R, Ji F, et al
    MiR-125b Loss Activated HIF1alpha/pAKT Loop, Leading to Trans-Arterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Hepatology. 2020 Jul 1. doi: 10.1002/hep.31448.
    PubMed     Abstract available


  312. WANG Y
    Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
    Hepatology. 2020;72:365.
    PubMed    


  313. LI L, Wei Y, Wang H
    REPLY.
    Hepatology. 2020;72:366.
    PubMed    


  314. HOOFNAGLE JH
    FXR Agonists as Therapy for Liver Disease.
    Hepatology. 2020;72:1-3.
    PubMed    


  315. MALLAT A, Lotersztajn S
    Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
    Hepatology. 2020;72:350-352.
    PubMed    


  316. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    PubMed    


  317. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    PubMed    


  318. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    PubMed    


  319. ARASE Y, Kagawa T, Tanaka A
    Reply.
    Hepatology. 2020;72:360-361.
    PubMed    


  320. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  321. PAPATHEODORIDIS GV, Voulgaris T, Papatheodoridi M, Kim WR, et al
    Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
    Hepatology. 2020 Jun 30. doi: 10.1002/hep.31440.
    PubMed     Abstract available


  322. KIM BK, Kim SU
    Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Jun 29. doi: 10.1002/hep.31439.
    PubMed     Abstract available


  323. WU J, Gao W, Tang Q, Yu Y, et al
    M2 macrophage-derived exosomes facilitate hepatocarcinoma metastasis by transferring alphaM beta2 integrin to tumor cells.
    Hepatology. 2020 Jun 28. doi: 10.1002/hep.31432.
    PubMed     Abstract available


  324. XU M, Ge C, Zhu L, Qin Y, et al
    iRhom2 promotes hepatic steatosis by activating MAP3K7-dependent pathway.
    Hepatology. 2020 Jun 26. doi: 10.1002/hep.31436.
    PubMed     Abstract available


  325. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available


  326. AKBULUT S, Sahin TT, Yilmaz S
    Comment on Alpha-Fetoprotein Decrease from > 1.000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31433.
    PubMed     Abstract available


  327. KLOECKNER R, Galle PR, Bruix J
    Local and Regional Therapies for Hepatocellular Carcinoma.
    Hepatology. 2020 Jun 18. doi: 10.1002/hep.31424.
    PubMed     Abstract available


  328. KIM YS, Nam HJ, Han CY, Joo MS, et al
    LXRalpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating ATG4B and Rab-8B, reducing mitochondrial fuel oxidation.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31423.
    PubMed     Abstract available


  329. RUSSO MW, Fix OK, Koteish AA, Duggan K, et al
    Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31425.
    PubMed     Abstract available


  330. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    PubMed     Abstract available


  331. ALFERINK LJ, Radjabzadeh D, Erler NS, Vojinovic D, et al
    Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population-based study of 1355 adults.
    Hepatology. 2020 Jun 12. doi: 10.1002/hep.31417.
    PubMed     Abstract available


  332. XIE C, Fang JH, Zhuang SM
    Reply to: Letter to the editor, "PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?" (HEP-20-0942).
    Hepatology. 2020 Jun 11. doi: 10.1002/hep.31300.
    PubMed     Abstract available


  333. MUNROE M, Niero EL, Fok WC, Vessoni AT, et al
    Telomere dysfunction activates p53 and represses HNF4alpha expression leading to impaired human hepatocyte development and function.
    Hepatology. 2020 Jun 9. doi: 10.1002/hep.31414.
    PubMed     Abstract available


  334. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    PubMed     Abstract available


  335. ZHAO N, Dang H, Ma L, Martin SP, et al
    Intratumoral gammadelta T-cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31412.
    PubMed     Abstract available


  336. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available


  337. PRABHU A, Cargill T, Roberts N, Ryan JD, et al
    Systematic review of the clinical outcomes of iron reduction in Hereditary Hemochromatosis.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31405.
    PubMed     Abstract available


  338. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    PubMed     Abstract available


  339. PATEL K, Chung C, Myers RP
    Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective?
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31402.
    PubMed     Abstract available


  340. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    PubMed     Abstract available


  341. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    PubMed     Abstract available


  342. JINDAL A, Sarin SK
    Letter to the Editors: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31400.
    PubMed     Abstract available


  343. THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
    Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
    PubMed     Abstract available


  344. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    PubMed    


    May 2020
  345. CALVISI DF
    Schistoma mansoni and Hepatocellular Carcinoma: is it all about c-Jun and STAT3?
    Hepatology. 2020 May 28. doi: 10.1002/hep.31392.
    PubMed     Abstract available


  346. HALL Z, Chiarugi D, Charidemou E, Leslie J, et al
    Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma.
    Hepatology. 2020 May 27. doi: 10.1002/hep.31391.
    PubMed     Abstract available


  347. SMITH JL, Rodriguez TC, Mou H, Kwan SY, et al
    YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells.
    Hepatology. 2020 May 26. doi: 10.1002/hep.31389.
    PubMed     Abstract available


  348. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available


  349. LLOVET JM, Villanueva A, Marrero JA, Schwartz M, et al
    Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference.
    Hepatology. 2020 May 20. doi: 10.1002/hep.31327.
    PubMed     Abstract available


  350. DEVARBHAVI H
    RE: Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy-Related? Casey et al. Hepatology 2020 Jan 28[Online ahead of print DOI: 10.1002/hep.31144.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31323.
    PubMed     Abstract available


  351. CHU S, Sun R, Gu X, Chen L, et al
    Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcoholic steatohepatitis in mice.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31321.
    PubMed     Abstract available


  352. NEWTON KP, Lavine JE, Wilson L, Behling C, et al
    Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31317.
    PubMed     Abstract available


  353. GABR A, Kulik L, Mouli S, Riaz A, et al
    Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
    PubMed     Abstract available


  354. VANDEL J, Dubois-Chevalier J, Gheeraert C, Derudas B, et al
    Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH).
    Hepatology. 2020 May 11. doi: 10.1002/hep.31312.
    PubMed     Abstract available


  355. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    PubMed     Abstract available


  356. FINN RS, Zhu AX
    Evolution of Systemic Therapy for Hepatocellular Carcinoma.
    Hepatology. 2020 May 7. doi: 10.1002/hep.31306.
    PubMed     Abstract available


  357. LI W
    Letter to the Editor: PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?
    Hepatology. 2020 May 7. doi: 10.1002/hep.31299.
    PubMed     Abstract available


  358. PISA JF, Brown RS Jr, Hirsova P, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1527-1529.
    PubMed    


  359. KAPLOWITZ N, Than TA, Win S
    Acetaminophen Hepatotoxicity: Strong Offense and Weakened Defense.
    Hepatology. 2020;71:1530-1532.
    PubMed    


  360. RAEVENS S, Fallon MB
    PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension.
    Hepatology. 2020;71:1870-1872.
    PubMed    


  361. HENSON JB, Roden M, Targher G, Corey KE, et al
    Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.
    Hepatology. 2020;71:1867-1869.
    PubMed    


  362. ABERG F, Farkkila M, Salomaa V, Jula A, et al
    REPLY.
    Hepatology. 2020;71:1888-1889.
    PubMed    


  363. GOW P, Testro AG, Hey P, Sinclair M, et al
    Letter to the Editor: Moderate Alcohol Use in Fatty Liver Disease: Don't Throw the Cabernet Out With the Bathwater.
    Hepatology. 2020;71:1887-1888.
    PubMed    


  364. MA Y, Brown PM, Rotman Y
    REPLY.
    Hepatology. 2020;71:1886-1887.
    PubMed    


  365. GALMOZZI E
    Letter to the Editor: Does the HSD17B13 rs72613567 Splice Variant Actually Yield a New Type of Alternative Splicing?
    Hepatology. 2020;71:1885-1886.
    PubMed    


  366. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    PubMed    


  367. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
    Epidemiological Features of NAFLD From 1999 to 2018 in China.
    Hepatology. 2020;71:1851-1864.
    PubMed     Abstract available


  368. CHEN Y, Liu K, Zhang J, Hai Y, et al
    c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
    Hepatology. 2020;71:1787-1801.
    PubMed     Abstract available


  369. GAO W, Jia Z, Tian Y, Yang P, et al
    HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Hepatology. 2020;71:1678-1695.
    PubMed     Abstract available


  370. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
    Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Hepatology. 2020;71:1696-1711.
    PubMed     Abstract available


  371. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
    A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Hepatology. 2020;71:1660-1677.
    PubMed     Abstract available


    April 2020
  372. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available


  373. FONDEVILA MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, et al
    The L-alpha-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31290.
    PubMed     Abstract available


  374. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    PubMed     Abstract available


  375. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available


  376. KUMAR A
    Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31285.
    PubMed     Abstract available


  377. KARDASHIAN A, Agopian V
    Reply to: "Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?"
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31283.
    PubMed     Abstract available


  378. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    PubMed     Abstract available


  379. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31279.
    PubMed     Abstract available


  380. FIX OK, Hameed B, Fontana RJ, Kwok RM, et al
    Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.
    PubMed     Abstract available


  381. ZHANG L, Tian R, Yao X, Zhang XJ, et al
    Milk Fat Globule-EGF Factor 8 improves Hepatic Steatosis and Inflammation.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31277.
    PubMed     Abstract available


  382. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    PubMed     Abstract available


  383. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  384. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    PubMed     Abstract available


  385. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    PubMed     Abstract available


  386. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    PubMed     Abstract available


  387. LAPUMNUAYPOL K, Danford CJ, Lau DTY, Pisa JF, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1143-1145.
    PubMed    


  388. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    PubMed    


  389. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    PubMed    


  390. HILSCHER MB, Shah VH
    Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases.
    Hepatology. 2020;71:1501-1504.
    PubMed    


  391. YKI-JARVINEN H
    Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Hepatology. 2020;71:1499-1501.
    PubMed    


  392. HAJIFATHALIAN K, Torabi Sagvand B, McCullough A
    Reply.
    Hepatology. 2020;71:1526.
    PubMed    


  393. BRAILLON A
    Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?
    Hepatology. 2020;71:1525.
    PubMed    


  394. CARVAO J, Jasmins L
    Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
    Hepatology. 2020;71:1522-1523.
    PubMed    


  395. KHALAF RT, Sokol RJ
    New Insights Into Intestinal Failure-Associated Liver Disease in Children.
    Hepatology. 2020;71:1486-1498.
    PubMed     Abstract available


  396. XIONG X, Kuang H, Liu T, Lin JD, et al
    A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Hepatology. 2020;71:1467-1473.
    PubMed    


  397. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
    Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
    Hepatology. 2020;71:1474-1485.
    PubMed     Abstract available


  398. XIONG J, Liu T, Mi L, Kuang H, et al
    hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
    Hepatology. 2020;71:1228-1246.
    PubMed     Abstract available


  399. LIU J, Wu Z, Han D, Wei C, et al
    Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
    Hepatology. 2020;71:1262-1278.
    PubMed     Abstract available


  400. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available


  401. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
    Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Hepatology. 2020;71:1213-1227.
    PubMed     Abstract available


  402. ZHANG C, Lin R, Li Z, Yang S, et al
    Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Hepatology. 2020;71:1297-1315.
    PubMed     Abstract available


  403. SHIGETA K, Datta M, Hato T, Kitahara S, et al
    Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2020;71:1247-1261.
    PubMed     Abstract available


    March 2020
  404. LIU Y, Yang W, VoPham T, Ma Y, et al
    Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31251.
    PubMed     Abstract available


  405. QIN J, Wang H, Qin X, Zhang P, et al
    Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.
    Hepatology. 2020 Mar 27. doi: 10.1002/hep.31257.
    PubMed     Abstract available


  406. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
    Immunotherapy as a downstaging therapy for liver transplantation.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
    PubMed     Abstract available


  407. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available


  408. STENDER S, Loomba R
    PNPLA3 Genotype and Risk of Liver and All-Cause Mortality.
    Hepatology. 2020;71:777-779.
    PubMed    


  409. TANER T, Heimbach JK
    Something Wicked this Way Comes.
    Hepatology. 2020;71:1119-1121.
    PubMed    


  410. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    PubMed    


  411. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    PubMed    


  412. RIZVI S, Gores GJ
    The Two Faces of Relaxin in Cancer: Antitumor or Protumor?
    Hepatology. 2020;71:1117-1119.
    PubMed    


  413. SUGIYAMA T
    Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
    Hepatology. 2020;71:1131-1132.
    PubMed    


  414. ARASE Y, Kagawa T
    Reply.
    Hepatology. 2020;71:1132-1133.
    PubMed    


  415. YANG D, Yan J, Weng J
    Reply.
    Hepatology. 2020;71:1129.
    PubMed    


  416. LU ZN, Han ZG
    Reply.
    Hepatology. 2020;71:1130-1131.
    PubMed    


  417. WANG JB, Bai ZF, Xiao XH
    Letter to the Editor: Is Aristolochic Acid the Major Cause of Liver Cancer in China and Asia?
    Hepatology. 2020;71:1130.
    PubMed    


  418. SPANN A, Yasodhara A, Kang J, Watt K, et al
    Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.
    Hepatology. 2020;71:1093-1105.
    PubMed     Abstract available


  419. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available


  420. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available


  421. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available


  422. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available


  423. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available


  424. ABERG F, Puukka P, Salomaa V, Mannisto S, et al
    Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.
    Hepatology. 2020;71:835-848.
    PubMed     Abstract available


    February 2020
  425. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
    Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
    PubMed     Abstract available


  426. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    PubMed    


  427. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    PubMed    


  428. HASSAN S, Sebastian S, Maharjan S, Lesha A, et al
    Liver-on-a-Chip Models of Fatty Liver Disease.
    Hepatology. 2020;71:733-740.
    PubMed    


  429. SANDAHL TD, Laursen TL, Munk DE, Vilstrup H, et al
    The Prevalence of Wilson's Disease: An Update.
    Hepatology. 2020;71:722-732.
    PubMed     Abstract available


  430. ARASE Y, Tsuruya K, Hirose S, Ogiwara N, et al
    Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.
    Hepatology. 2020;71:757-759.
    PubMed    


  431. PENRICE D, Simonetto DA
    Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies.
    Hepatology. 2020;71:760-761.
    PubMed    


  432. BAIGES A, Turon F, Simon-Talero M, Tasayco S, et al
    Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.
    Hepatology. 2020;71:658-669.
    PubMed     Abstract available


  433. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available


  434. ALLEN AM, Shah VH, Therneau TM, Venkatesh SK, et al
    The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Hepatology. 2020;71:510-521.
    PubMed     Abstract available


  435. ARORA V, Maiwall R, Rajan V, Jindal A, et al
    Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Hepatology. 2020;71:600-610.
    PubMed     Abstract available


    January 2020
  436. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
    Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
    Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
    PubMed     Abstract available


  437. NEUSCHWANDER-TETRI BA
    Too Much Sugar-The Not-So-Sweet Reality of Its Impact on Our Health.
    Hepatology. 2020;71:377-379.
    PubMed    


  438. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    PubMed    


  439. CHEUNG AC, Walker DI, Juran BD, Miller GW, et al
    Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.
    Hepatology. 2020;71:352-362.
    PubMed    


  440. SHANG L, Mashek DG
    The Underpinnings of PNPLA3-Mediated Fatty Liver Emerge.
    Hepatology. 2020;71:375-377.
    PubMed    


  441. JANSSON-KNODELL CL, Gawrieh S, McIntyre AD, Liang T, et al
    Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:383-385.
    PubMed    


  442. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    PubMed     Abstract available


  443. KWAN SY, Sheel A, Song CQ, Zhang XO, et al
    Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.
    Hepatology. 2020;71:275-290.
    PubMed     Abstract available


  444. LAITINEN TT, Vahtera J, Pahkala K, Magnussen CG, et al
    Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study.
    Hepatology. 2020;71:67-75.
    PubMed     Abstract available


  445. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    PubMed     Abstract available


    December 2019
  446. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


    November 2019
  447. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
    Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
    PubMed     Abstract available


  448. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
    Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
    Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
    PubMed     Abstract available


  449. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
    Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
    PubMed     Abstract available


  450. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


    October 2019
  451. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available


  452. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available


    September 2019
  453. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  454. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  455. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available


  456. BI X, Deising A, Frenette C
    Acute Liver Failure from Exertional Heatstroke Can Result in Excellent Long-term Survival with Liver Transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30938.
    PubMed     Abstract available


  457. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


    August 2019
  458. KWON HM, Moon YJ, Jung KW, Park YS, et al
    Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
    PubMed     Abstract available


  459. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


  460. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


    July 2019
  461. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  462. CHOUDHARY NS, Saigal S, Soin AS
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30869.
    PubMed     Abstract available


  463. MARRERO JA
    Obesity and Liver Disease: The New Era of Liver Transplantation.
    Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854.
    PubMed     Abstract available


    June 2019
  464. FIRL DJ, Sasaki K, Agopian VG, Gorgen A, et al
    Charting the Path Forward for Risk Prediction in Liver Transplant for HCC: International Validation of HALTHCC amongst 4,089 patients.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30838.
    PubMed     Abstract available


  465. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    PubMed     Abstract available


  466. GALANTE A, Adeyi O, Lau L, Humar A, et al
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jun 4. doi: 10.1002/hep.30803.
    PubMed     Abstract available


    May 2019
  467. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    PubMed     Abstract available


  468. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    PubMed     Abstract available


  469. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  470. LEVITSKY J, Asrani SK, Abecassis M, Ruiz R, et al
    External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation.
    Hepatology. 2019 Apr 19. doi: 10.1002/hep.30667.
    PubMed     Abstract available


    March 2019
  471. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  472. SINHA J, Mehta N, Dodge JL, Poltavskiy E, et al
    Are There Upper Limits in Tumor Burden for Down-staging of HCC to Liver Transplant? Analysis of the All-comers Protocol.
    Hepatology. 2019 Feb 19. doi: 10.1002/hep.30570.
    PubMed     Abstract available


    January 2019
  473. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    PubMed     Abstract available


    December 2018
  474. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    PubMed     Abstract available


  475. GONG S, Yan Z, Liu Z, Niu M, et al
    Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30361.
    PubMed     Abstract available


    November 2018
  476. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Abstract available


    September 2018
  477. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Abstract available


    August 2018
  478. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  479. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


    July 2018
  480. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Abstract available


  481. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


    May 2018
  482. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: